Northern Trust Announces Quarterly Dividend Increase From $0.70 To $0.75

Northern Trust Corporation today commented on the results of the Federal Reserve's 2022 Comprehensive Capital Analysis and Review (CCAR) and announced plans to increase its quarterly common stock dividend

byMichael Horton

June 27, 2022

1 minute read

Northern Trust Corporation today commented on the results of the Federal Reserve’s 2022 Comprehensive Capital Analysis and Review (CCAR) and announced plans to increase its quarterly common stock dividend from $0.70 to $0.75 per common share, beginning in the third quarter of 2022.

Tudor Pickering Downgrades Dril-Quip to Hold

By Benzinga Newsdesk

Today, 4:20 AM

Tudor Pickering analyst Taylor Zurcher downgrades Dril-Quip (NYSE:DRQ) from Buy to Hold.

DRQ

FreightCar America Q4 EPS $0.06 Beats $(0.15) Estimate, Sales $75.02M Beat $67.00M Estimate

By Benzinga Newsdesk

Today, 4:20 AM

FreightCar America (NASDAQ:RAIL) reported quarterly earnings of $0.06 per share which beat the analyst consensus estimate of $(0.15) by 140 percent. This is a 185.71 percent increase over losses of $(0.07) per share from

RAIL

Lack Of E-Commerce Visibility Leads To Squarespace Downgrade, Analyst Says

By Anusuya Lahiri

Today, 4:20 AM

KeyBanc analyst Josh Beck downgraded Squarespace, Inc (NYSE:SQSP) to Sector Weight from Overweight without a price target. The re-rating reflected a more…

AMZN

Rigel Announces U.S. FDA Approval Of REZLIDHIA (olutasidenib) For Treatment Of Adult Patients With Relapsed Or Refractory Acute Myeloid Leukemia With a Susceptible IDH1 Mutation

By Michael Horton

Today, 4:20 AM

Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) today announced that the U.S. Food and Drug Administration (FDA) has approved REZLIDHIA™ (olutasidenib) capsules for the treatment of adult patients with relapsed or

RIGL

Northern Trust Announces Quarterly Dividend Increase From $0.70 To $0.75

Related Posts

Tudor Pickering Downgrades Dril-Quip to Hold

FreightCar America Q4 EPS $0.06 Beats $(0.15) Estimate, Sales $75.02M Beat $67.00M Estimate

Lack Of E-Commerce Visibility Leads To Squarespace Downgrade, Analyst Says

Rigel Announces U.S. FDA Approval Of REZLIDHIA (olutasidenib) For Treatment Of Adult Patients With Relapsed Or Refractory Acute Myeloid Leukemia With a Susceptible IDH1 Mutation